{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T16:55:03Z","timestamp":1788540903862,"version":"build-2803163510"},"reference-count":42,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,1,18]],"date-time":"2021-01-18T00:00:00Z","timestamp":1610928000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Schizophrenia Research"],"published-print":{"date-parts":[[2021,2]]},"DOI":"10.1016\/j.schres.2020.12.006","type":"journal-article","created":{"date-parts":[[2021,1,13]],"date-time":"2021-01-13T17:34:29Z","timestamp":1610559269000},"page":"198-205","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":30,"special_numbering":"C","title":["Safety and tolerability of lumateperone 42\u00a0mg: An open-label antipsychotic switch study in outpatients with stable schizophrenia"],"prefix":"10.1016","volume":"228","author":[{"given":"Christoph U.","family":"Correll","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimberly E.","family":"Vanover","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert E.","family":"Davis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Satlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharon","family":"Mates","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.schres.2020.12.006_bb0005","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1186\/s12888-018-1856-y","article-title":"Patient preferences concerning the efficacy and side-effect profile of schizophrenia medications: a survey of patients living with schizophrenia","volume":"18","author":"Achtyes","year":"2018","journal-title":"BMC psychiatry"},{"key":"10.1016\/j.schres.2020.12.006_bb0010","series-title":"Diagnostic and Statistical Manual of Mental Disorders","author":"American Psychiatric Association","year":"2013"},{"issue":"4","key":"10.1016\/j.schres.2020.12.006_bb0015","first-page":"171","article-title":"Attitude of family to neuroleptics","volume":"26","author":"Angermeyer","year":"1999","journal-title":"Psychiatr. Prax."},{"issue":"5","key":"10.1016\/j.schres.2020.12.006_bb0020","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1192\/bjp.154.5.672","article-title":"A rating scale for drug-induced akathisia","volume":"154","author":"Barnes","year":"1989","journal-title":"Br. J. Psychiatry"},{"issue":"1","key":"10.1016\/j.schres.2020.12.006_bb0025","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1186\/1477-7525-6-105","article-title":"Impact of schizophrenia and schizophrenia treatment-related adverse events on quality of life: direct utility elicitation","volume":"6","author":"Briggs","year":"2008","journal-title":"Health Qual. Life Outcomes"},{"issue":"6","key":"10.1016\/j.schres.2020.12.006_bb0030","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1093\/schbul\/sby058","article-title":"Global epidemiology and burden of schizophrenia: findings from the Global Burden of Disease Study 2016","volume":"44","author":"Charlson","year":"2018","journal-title":"Schizophr. Bull."},{"issue":"Suppl. 2","key":"10.1016\/j.schres.2020.12.006_bb0035","doi-asserted-by":"crossref","first-page":"S12","DOI":"10.1016\/S0924-9338(10)71701-6","article-title":"From receptor pharmacology to improved outcomes: individualising the selection, dosing, and switching of antipsychotics","volume":"25","author":"Correll","year":"2010","journal-title":"Eur. Psychiatry"},{"issue":"2","key":"10.1016\/j.schres.2020.12.006_bb0040","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1002\/wps.20204","article-title":"Effects of antipsychotics, antidepressants and mood stabilizers on risk for physical diseases in people with schizophrenia, depression and bipolar disorder","volume":"14","author":"Correll","year":"2015","journal-title":"World Psychiatry"},{"issue":"2","key":"10.1016\/j.schres.2020.12.006_bb0045","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1002\/wps.20420","article-title":"Prevalence, incidence and mortality from cardiovascular disease in patients with pooled and specific severe mental illness: a large-scale meta-analysis of 3,211,768 patients and 113,383,368 controls","volume":"16","author":"Correll","year":"2017","journal-title":"World Psychiatry"},{"issue":"4","key":"10.1016\/j.schres.2020.12.006_bb0050","first-page":"349","article-title":"Efficacy and safety of lumateperone for treatment of schizophrenia: a randomized clinical trial","volume":"77","author":"Correll","year":"2020","journal-title":"JAMA Psych."},{"issue":"6","key":"10.1016\/j.schres.2020.12.006_bb0055","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1080\/14737175.2016.1174577","article-title":"ITI-007 in the treatment of schizophrenia: from novel pharmacology to clinical outcomes","volume":"16","author":"Davis","year":"2016","journal-title":"Expert. Rev. Neurother."},{"issue":"15","key":"10.1016\/j.schres.2020.12.006_bb0060","doi-asserted-by":"crossref","first-page":"2863","DOI":"10.1007\/s00213-015-3922-1","article-title":"ITI-007 demonstrates brain occupancy at serotonin 5-HT2A and dopamine D 2 receptors and serotonin transporters using positron emission tomography in healthy volunteers","volume":"232","author":"Davis","year":"2015","journal-title":"Psychopharmacology"},{"issue":"2","key":"10.1016\/j.schres.2020.12.006_bb0065","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1038\/nrendo.2011.156","article-title":"Metabolic and cardiovascular adverse effects associated with antipsychotic drugs","volume":"8","author":"De Hert","year":"2012","journal-title":"Nat. Rev. Endocrinol."},{"key":"10.1016\/j.schres.2020.12.006_bb0070","doi-asserted-by":"crossref","unstructured":"Demyttenaere, K., Detraux, J., Racagni, G., Vansteelandt, K., 2019. Medication-induced akathisia with newly approved antipsychotics in patients with a severe mental illness: a systematic review and meta-analysis. CNS Drugs, 1-18.","DOI":"10.1007\/s40263-019-00625-3"},{"issue":"1","key":"10.1016\/j.schres.2020.12.006_bb0075","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/1471-244X-12-20","article-title":"A patient perspective of the impact of medication side effects on adherence: results of a cross-sectional nationwide survey of patients with schizophrenia","volume":"12","author":"DiBonaventura","year":"2012","journal-title":"BMC psychiatry"},{"key":"10.1016\/j.schres.2020.12.006_bb0080","series-title":"Lumateperone (ITI-007) in the treatment of bipolar depression: results from a randomized clinical trial [Poster 123], 58th Annual American College of Neuropsychopharmacology Meeting","author":"Durgam","year":"2019"},{"key":"10.1016\/j.schres.2020.12.006_bb0085","series-title":"Assessment Manual for Psychopharmacology","author":"ECDEU","year":"1976"},{"key":"10.1016\/j.schres.2020.12.006_bb0090","doi-asserted-by":"crossref","unstructured":"Huhn, M., Nikolakopoulou, A., Schneider-Thoma, J., Krause, M., Samara, M., Peter, N., Arndt, T., B\u00e4ckers, L., Rothe, P., Cipriani, A., 2019. Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis. Lancet 394(10202), P939\u2013951.","DOI":"10.1016\/S0140-6736(19)31135-3"},{"key":"10.1016\/j.schres.2020.12.006_bb0095","doi-asserted-by":"crossref","first-page":"15067","DOI":"10.1038\/nrdp.2015.67","article-title":"Schizophrenia","volume":"1","author":"Kahn","year":"2015","journal-title":"Nat Rev Dis Primers"},{"issue":"5","key":"10.1016\/j.schres.2020.12.006_bb0100","doi-asserted-by":"crossref","first-page":"627","DOI":"10.4088\/JCP.08r04210","article-title":"Akathisia: an updated review focusing on second-generation antipsychotics","volume":"70","author":"Kane","year":"2009","journal-title":"J. Clin. Psychiatry"},{"issue":"3","key":"10.1016\/j.schres.2020.12.006_bb0105","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1002\/wps.20060","article-title":"Non-adherence to medication in patients with psychotic disorders: epidemiology, contributing factors and management strategies","volume":"12","author":"Kane","year":"2013","journal-title":"World Psychiatry"},{"issue":"2","key":"10.1016\/j.schres.2020.12.006_bb0110","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1093\/schbul\/13.2.261","article-title":"The positive and negative syndrome scale (PANSS) for schizophrenia","volume":"13","author":"Kay","year":"1987","journal-title":"Schizophr. Bull."},{"issue":"9896","key":"10.1016\/j.schres.2020.12.006_bb0115","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/S0140-6736(13)60733-3","article-title":"Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis","volume":"382","author":"Leucht","year":"2013","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.schres.2020.12.006_bb0120","doi-asserted-by":"crossref","first-page":"2670","DOI":"10.1021\/jm401958n","article-title":"Discovery of a tetracyclic quinoxaline derivative as a potent and orally active multifunctional drug candidate for the treatment of neuropsychiatric and neurological disorders","volume":"57","author":"Li","year":"2014","journal-title":"J. Med. Chem."},{"issue":"12","key":"10.1016\/j.schres.2020.12.006_bb0125","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1056\/NEJMoa051688","article-title":"Effectiveness of antipsychotic drugs in patients with chronic schizophrenia","volume":"353","author":"Lieberman","year":"2005","journal-title":"N. Engl. J. Med."},{"issue":"12","key":"10.1016\/j.schres.2020.12.006_bb0130","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1016\/j.biopsych.2015.08.026","article-title":"ITI-007 for the treatment of schizophrenia: a 4-week randomized, double-blind, controlled trial","volume":"79","author":"Lieberman","year":"2016","journal-title":"Biol. Psychiatry"},{"issue":"1","key":"10.1016\/j.schres.2020.12.006_bb0135","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1186\/s12888-017-1213-6","article-title":"Assessing the burden of treatment-emergent adverse events associated with atypical antipsychotic medications","volume":"17","author":"Llorca","year":"2017","journal-title":"BMC psychiatry"},{"issue":"18","key":"10.1016\/j.schres.2020.12.006_bb0140","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1056\/NEJMra1808803","article-title":"Schizophrenia","volume":"381","author":"Marder","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"Suppl. 3","key":"10.1016\/j.schres.2020.12.006_bb0145","doi-asserted-by":"crossref","first-page":"5","DOI":"10.4088\/JCP.7075su1c.02","article-title":"Understanding needs, interactions, treatment, and expectations among individuals affected by bipolar disorder or schizophrenia: the UNITE global survey","volume":"70","author":"McIntyre","year":"2009","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.schres.2020.12.006_bb0150","doi-asserted-by":"crossref","first-page":"263","DOI":"10.2147\/PPA.S6053","article-title":"Antipsychotic adherence, switching, and health care service utilization among Medicaid recipients with schizophrenia","volume":"4","author":"Noordsy","year":"2010","journal-title":"Patient Prefer Adherence"},{"issue":"1","key":"10.1016\/j.schres.2020.12.006_bb0155","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1186\/1471-244X-10-75","article-title":"Predictors of switching antipsychotic medications in the treatment of schizophrenia","volume":"10","author":"Nyhuis","year":"2010","journal-title":"BMC psychiatry"},{"issue":"12","key":"10.1016\/j.schres.2020.12.006_bb0160","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1001\/jamapsychiatry.2015.1737","article-title":"Premature mortality among adults with schizophrenia in the United States","volume":"72","author":"Olfson","year":"2015","journal-title":"JAMA Psychiatry"},{"issue":"1","key":"10.1016\/j.schres.2020.12.006_bb0165","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/S2215-0366(19)30416-X","article-title":"Comparative effects of 18 antipsychotics on metabolic function in patients with schizophrenia, predictors of metabolic dysregulation, and association with psychopathology: a systematic review and network meta-analysis","volume":"7","author":"Pillinger","year":"2020","journal-title":"Lancet Psychiatry"},{"issue":"1","key":"10.1016\/j.schres.2020.12.006_bb0170","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/1744-859X-12-42","article-title":"Reasons and clinical outcomes of antipsychotic treatment switch in outpatients with schizophrenia in real-life clinical settings: the ETOS observational study","volume":"12","author":"Roussidis","year":"2013","journal-title":"Ann. General Psychiatry"},{"key":"10.1016\/j.schres.2020.12.006_bb0175","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/j.1600-0447.1970.tb02066.x","article-title":"A rating scale for extrapyramidal side effects","volume":"212","author":"Simpson","year":"1970","journal-title":"Acta psychiatrica Scandinavica. Supplementum"},{"issue":"3","key":"10.1016\/j.schres.2020.12.006_bb0180","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1007\/s00213-014-3704-1","article-title":"Functional profile of a novel modulator of serotonin, dopamine, and glutamate neurotransmission","volume":"232","author":"Snyder","year":"2015","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.schres.2020.12.006_bb0185","doi-asserted-by":"crossref","first-page":"757","DOI":"10.2147\/TCRM.S117321","article-title":"Safety, tolerability, and risks associated with first-and second-generation antipsychotics: a state-of-the-art clinical review","volume":"13","author":"Solmi","year":"2017","journal-title":"Ther. Clin. Risk Manag."},{"issue":"1","key":"10.1016\/j.schres.2020.12.006_bb0190","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1002\/wps.20699","article-title":"20-year follow-up study of physical morbidity and mortality in relationship to antipsychotic treatment in a nationwide cohort of 62,250 patients with schizophrenia (FIN20)","volume":"19","author":"Taipale","year":"2020","journal-title":"World Psychiatry"},{"issue":"3","key":"10.1016\/j.schres.2020.12.006_bb0195","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1002\/wps.20252","article-title":"Risk of metabolic syndrome and its components in people with schizophrenia and related psychotic disorders, bipolar disorder and major depressive disorder: a systematic review and meta-analysis","volume":"14","author":"Vancampfort","year":"2015","journal-title":"World Psychiatry"},{"issue":"2","key":"10.1016\/j.schres.2020.12.006_bb0200","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1002\/wps.20309","article-title":"Diabetes mellitus in people with schizophrenia, bipolar disorder and major depressive disorder: a systematic review and large scale meta-analysis","volume":"15","author":"Vancampfort","year":"2016","journal-title":"World Psychiatry"},{"issue":"3","key":"10.1016\/j.schres.2020.12.006_bb0205","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1038\/s41386-018-0251-1","article-title":"Dopamine D2 receptor occupancy of lumateperone (ITI-007): a positron emission tomography study in patients with schizophrenia","volume":"44","author":"Vanover","year":"2019","journal-title":"Neuropsychopharmacology"},{"issue":"10100","key":"10.1016\/j.schres.2020.12.006_bb0210","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1016\/S0140-6736(17)32154-2","article-title":"Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990\u20132016: a systematic analysis for the Global Burden of Disease Study 2016","volume":"390","author":"Vos","year":"2017","journal-title":"Lancet"}],"container-title":["Schizophrenia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920996420306356?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920996420306356?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T19:41:30Z","timestamp":1760298090000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0920996420306356"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2]]},"references-count":42,"alternative-id":["S0920996420306356"],"URL":"https:\/\/doi.org\/10.1016\/j.schres.2020.12.006","relation":{},"ISSN":["0920-9964"],"issn-type":[{"value":"0920-9964","type":"print"}],"subject":[],"published":{"date-parts":[[2021,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety and tolerability of lumateperone 42\u00a0mg: An open-label antipsychotic switch study in outpatients with stable schizophrenia","name":"articletitle","label":"Article Title"},{"value":"Schizophrenia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.schres.2020.12.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Intra-Cellular Therapies, Inc. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}